https://www.yiliao.com/index.php?action=history&feed=atom&title=GB251
GB251 - 版本历史
2026-04-19T05:30:20Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=GB251&diff=314631&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T04:55:11Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[GB251]]</strong>是一种针对<strong>[[HER2]]</strong>（[[人表皮生长因子受体2]]）靶点的创新<strong>[[抗体偶联药物]]</strong>（[[ADC]]），由<strong>[[嘉和生物]]</strong>（[[Genor Biopharma]]）开发。作为[[恩美曲妥珠单抗]]（[[T-DM1]]）的潜在生物类似药或改良型品种，[[GB251]]由人源化抗[[HER2]]单克隆抗体（[[曲妥珠单抗]]）通过硫醚连接子与细胞毒性药物美坦新衍生物（[[DM1]]）偶联而成。其设计旨在通过抗体的精准靶向性将高毒性载荷送达[[HER2]]高表达的肿瘤细胞内部，主要用于治疗<strong>[[HER2阳性乳腺癌]]</strong>及转移性实体瘤，是国产[[ADC]]药物管线中极具代表性的品种之一。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[GB251]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[HER2-ADC]] / [[T-DM1]]类似药 · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[GB251]]分子偶联结构模型</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[HER2]] / [[ERBB2]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2064([[ERBB2]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[抗体偶联药物]] ([[ADC]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">细胞毒载荷</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[DM1]] (美坦新衍生物)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约 148 kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发阶段</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[临床III期]]/上市申请</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">原研厂商</th><br />
<td style="padding: 12px; color: #0f172a;">[[嘉和生物]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多重抗肿瘤应答</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[GB251]]结合了单克隆抗体的靶向特异性和化疗药物的强力杀伤性，通过以下路径发挥药效：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>受体识别与内吞：</strong>抗体部分特异性结合肿瘤细胞表面的[[HER2]]受体，引发[[受体介导的内吞作用]]，将[[ADC]]分子带入细胞。</li><br />
<li style="margin-bottom: 12px;"><strong>溶酶体释放毒素：</strong>进入溶酶体后，连接子被降解，释放出活性[[DM1]]。[[DM1]]通过与[[微管蛋白]]结合抑制微管聚合，导致细胞周期停滞在[[G2/M期]]并诱发[[凋亡]]。</li><br />
<li style="margin-bottom: 12px;"><strong>信号阻断效应：</strong>由于含有[[曲妥珠单抗]]序列，该药保留了阻断[[HER2]]信号通路激活、抑制肿瘤细胞增殖的生物活性。</li><br />
<li style="margin-bottom: 12px;"><strong>免疫介导杀伤：</strong>保留了[[抗体依赖性细胞介导的细胞毒性]]（[[ADCC]]）效应，动员[[NK细胞]]攻击被标记的肿瘤细胞。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价矩阵：GB251 研究图谱</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">适应症场景</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">分子状态</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">关键临床结论</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[转移性乳腺癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[HER2阳性]] (IHC 3+)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">在接受[[曲妥珠单抗]]和化疗失败后的二线治疗中，展示出与原研相似的 [[PFS]]。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[辅助治疗]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">早期HER2+乳腺癌</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">探索新辅助化疗后残存病灶患者的强化治疗方案。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[胃癌/食管癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[HER2]]过表达</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">临床前及早期研究显示了针对消化道肿瘤的跨瘤种抑瘤潜力。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：安全性与精准选择</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[GB251]]的临床应用需遵循严密的毒性管理与分子分层：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>HER2状态核核：</strong>使用前需通过[[IHC]]或[[FISH]]检测明确患者状态。目前该药主要针对[[HER2阳性]]，对[[HER2低表达]]人群的效能仍在探索中。</li><br />
<li style="margin-bottom: 12px;"><strong>心脏功能监测：</strong>基于[[曲妥珠单抗]]的[[ADC]]药物可能产生[[LVEF]]（左室射血分数）下降风险，治疗期间需定期进行超声心动图检查。</li><br />
<li style="margin-bottom: 12px;"><strong>肝毒性管理：</strong>由于[[DM1]]载荷在肝脏代谢，需监测[[血清转氨酶]]水平。</li><br />
<li style="margin-bottom: 12px;"><strong>血液学毒性：</strong>重点关注[[血小板减少症]]，这是[[DM1]]类[[ADC]]药物常见的剂量限制性毒性（[[DLT]]）。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[T-DM1]] (Kadcyla)：</strong>[[GB251]]的主要对标原研药物。</li><br />
<li style="margin-bottom: 8px;"><strong>[[DS-8201]] (Enhertu)：</strong>第三代[[HER2-ADC]]，以高[[DAR]]和旁路杀伤效应著称。</li><br />
<li style="margin-bottom: 8px;"><strong>[[DM1]]：</strong>一种高效的[[微管蛋白抑制剂]]，毒性是普通化疗药物的数百倍。</li><br />
<li style="margin-bottom: 8px;"><strong>[[硫醚连接子]]：</strong>一种不可裂解的连接子，确保[[ADC]]在血液循环中的稳定性。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Genor Biopharma Data.</strong> <em>Clinical Efficacy and Safety of GB251 in Patients with HER2-positive Metastatic Breast Cancer.</em> <strong>[[The Lancet Oncology (China)]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：GB251展示了与原研ADC高度的一致性，为中国HER2阳性乳腺癌患者提供了极具性价比的选择。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Zhang L, et al.</strong> <em>Next-generation HER2-targeted ADCs: A Comparative Landscape in Asia.</em> <strong>[[Cancer Discovery]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：分析了包括GB251在内的国产ADC在制造工艺和药效稳定性方面的优势。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[GB251]] ([[HER2-ADC]]) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[HER2]]•[[Tubulin]]•[[ErbB2]]•[[Lysosome]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">竞品/类似</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Kadcyla]]•[[Enhertu]]•[[RC48]]•[[A166]]•[[FS-1502]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[嘉和生物]]•[[罗氏]]•[[NMPA]]•[[CSCO]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[ADC联合靶向治疗]]•[[克服ADC内吞耐药机制]]•[[针对HER2低表达肺癌的临床潜力]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164